UTMD Enhances Targeting of Diclofenac and Doxil to Boost Tumor Immunotherapy

The study explores a novel combination therapy using ultrasound-targeted microbubble destruction (UTMD) with nanobubble-encapsulated diclofenac (DNBs) to enhance tumor immunotherapy. This approach improves the tumor immune microenvironment by reducing lactate secretion and immunosuppressive cells, while increasing the uptake of Doxil® and promoting T cell responses. The therapy significantly decreases M2 tumor-associated macrophages to 22% and myeloid-derived suppressor cells to 5.3%, while increasing CD8+ T cells to 51.1% and CD4+ T cells to 24.1%, resulting in a synergistic anti-tumor effect. Although the study is limited by its use of a single mouse cancer model and technical challenges, it offers promising insights for improving cancer treatment by modulating the tumor microenvironment and enhancing immune responses.